| yao, herui |
NCT06278870: Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial |
|
|
| Recruiting | 3 | 312 | RoW | disitamab vedotin, RC-48, Pyrotinib, trastuzumab, Pertuzumab, taxane drug | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2-positive Metastatic Breast Cancer, First-line Treatment | 06/31 | 06/31 | | |
NCT06316531: A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer |
|
|
| Recruiting | 3 | 268 | RoW | BL-M07D1, T-DM1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HER2-positive Breast Cancer | 05/26 | 05/26 | | |
SHR-A1811-III-301, NCT05424835: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane |
|
|
| Active, not recruiting | 3 | 381 | RoW | SHR-A1811, Pyrotinib in combination with Capecitabine. | Jiangsu HengRui Medicine Co., Ltd. | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | 12/26 | 12/27 | | |
NCT04263298: Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 210 | RoW | Fulvestrant, Experimental group, Capecitabine Oral Product, Active Comparator control group | Herui Yao | Metastatic Breast Cancer | 05/25 | 05/30 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
2019-KY-049, NCT04034589: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 46 | RoW | Pyrotinib combined with fulvestrant | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Metastatic Breast Cancer | 07/21 | 07/22 | | |
NCT04541251: Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC |
|
|
| Recruiting | 2 | 40 | RoW | Camrelizumab + Nab-paclitaxel + Carboplatin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangdong Provincial People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University | Lung Cancer, Non-small Cell, Artificial Intelligence | 07/22 | 09/23 | | |
NCT05068141: A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) |
|
|
| Recruiting | 2 | 79 | RoW | SG001, Nab-paclitaxel | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Triple Negative Breast Cancer | 10/22 | 10/23 | | |
BL-M07D1-205, NCT06445400: A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | BL-M07D1, Pertuzumab, Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HER2-positive Breast Cancer | 06/26 | 06/26 | | |
NCT05895864: Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 2 | 34 | RoW | utidelone injection, UTD1 injection | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Metastatic Urothelial Carcinoma | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
NCT06431243: A Clinical Study of Puesta Mesylate for Injection in Patients With Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 120 | RoW | A group Purinostat Mesylate 6mg/m2, A group Purinostat Mesylate 8.4mg/m2, A group Purinostat Mesylate 11.2mg/m2, A group Purinostat Mesylate 15.0mg/m2, B group Purinostat Mesylate 6.0mg/m2, B group Purinostat Mesylate 8.4 mg/m2, B group Purinostat Mesylate 11.2 mg/m2, B group Purinostat Mesylate 15.0 mg/m2 | Chengdu Zenitar Biomedical Technology Co., Ltd | Advanced Solid Tumor | 05/26 | 11/26 | | |
NCT06410703: CAN1012 Combined With PD-1 in Patients With Solid Tumors |
|
|
| Recruiting | 1/2 | 71 | RoW | CAN1012, Toripalimab | Canwell Biotech Limited | Advanced Solid Tumor | 05/25 | 05/26 | | |
NCT05273944: Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients |
|
|
| Recruiting | 1 | 80 | RoW | Doxorubicin Hydrochloride Liposome Injection, Caelyx®/Lipodox® | Shenzhen Kangzhe Pharmaceutical Co., Ltd., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Hunan Cancer Hospital, The Second Affiliated Hospital of Chongqing Medical University, First Affiliated Hospital of Jinan University, Zhejiang Provincial People's Hospital, Yuncheng Central Hospital, Shantou Central Hospital, Yuebei People's Hospital, Cancer Hospital of Guizhou Province, Guangzhou Panyu Central Hospital, Dongguan People's Hospital | Breast Cancer, Ovarian Cancer | 03/22 | 04/22 | | |
NCT04631835: Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 54 | RoW | HS-10352 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Breast Cancer | 04/23 | 08/23 | | |
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors |
|
|
| Active, not recruiting | 1 | 208 | US, RoW | BB-1701 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Locally Advanced/Metastatic HER2 Positive Solid Tumors | 08/24 | 12/24 | | |
GNC-035-103, NCT05160545: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 29 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 10/24 | 10/24 | | |
NCT06592417: To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 140 | RoW | JSKN016 injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Malignant Solid Tumor | 05/26 | 12/26 | | |
NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 12/24 | | |
NCT06332430: Intratumoral CAN2109 in Subjects With Solid Tumors |
|
|
| Recruiting | 1 | 27 | RoW | CAN2109 | Canwell Biotech Limited | Solid Tumor, Lymphoma | 05/25 | 05/26 | | |
NCT05461768: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M07D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Locally Advanced or Metastatic Solid Tumor | 12/24 | 12/24 | | |
| Not yet recruiting | 1 | 17 | RoW | KH801 | Beijing Kanghong Biopharmaceutical Co., Ltd. | Advanced Solid Tumors | 05/26 | 05/30 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
| Recruiting | 1 | 133 | RoW | SHR-4602 for injection | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumor | 05/25 | 05/26 | | |
NCT04003558: Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01) |
|
|
| Recruiting | N/A | 1500 | RoW | No interventions | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Tungwah Hospital of Sun Yat-Sen University, Shunde Hospital of Southern Medical University, Zhongshan Ophthalmic Center, Sun Yat-sen University | Breast Neoplasm Female, Early-stage Breast Cancer, Radiomics, Axillary Lymph Node, Survival, Prosthesis | 05/20 | 01/25 | | |
RBC-02, NCT04004559: MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis |
|
|
| Recruiting | N/A | 600 | RoW | No interventions | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Tungwah Hospital of Sun Yat-Sen University | Invasive Breast Cancer, Neoadjuvant Chemotherapy, Radiomics, Axillary Lymph Node, Prognosis | 10/20 | 05/25 | | |
NCT06241092: AI-Based Multimodal Multi-tasks Analysis Reveals Tumor Molecular Heterogeneity, Predicts Preoperative Lymph Node Metastasis and Prognosis in Papillary Thyroid Carcinoma |
|
|
| Recruiting | N/A | 256 | RoW | | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Papillary Thyroid Carcinoma; Molecular Heterogeneity; Multi-model Analysis; Artificial Intelligence; Lymph Node Metastases; Disease-free Survival | 09/24 | 01/25 | | |
NCT06510127: An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort Study |
|
|
| Enrolling by invitation | N/A | 840 | RoW | | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Jinan University | Breast Cancer | 06/25 | 01/26 | | |
NCT04511481: Deep Learning Magnetic Resonance Imaging Radiomic Predict Platinum-sensitive in Patients With Epithelial Ovarian Cancer |
|
|
| Recruiting | N/A | 93 | RoW | Radiomic Algorithm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Predictive Cancer Model | 08/20 | 01/21 | | |
NCT04535466: Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics |
|
|
| Recruiting | N/A | 1000 | RoW | | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Diseases, Artificial Intelligence, Dense Breast Density, Predictive Cancer Model | 09/20 | 09/20 | | |
| Recruiting | N/A | 358 | RoW | Locoregional surgery | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, First People's Hospital of Foshan | Breast Neoplasm Female, Surgery, Advanced Breast Cancer | 10/20 | 07/21 | | |
TOP-RLC, NCT04452058: CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC |
|
|
| Recruiting | N/A | 500 | RoW | Radiomic Algorithm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangdong Provincial People's Hospital | Predictive Cancer Model, Lung Cancer, Preinvasive Adenocarcinoma | 12/21 | 12/22 | | |
NCT05329597: Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | N/A | 88 | RoW | Genotyping | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University | Pharmacokinetics, Pancreatic Cancer, Gene Polymorphisms | 06/22 | 07/22 | | |
| Gong, Chang |
NCT06144944: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer |
|
|
| Recruiting | 3 | 160 | RoW | Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer | 06/26 | 12/31 | | |
NCT05760612: A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab |
|
|
| Recruiting | 3 | 300 | RoW | Trastuzumab and nelatinib, Trastuzumab and Parstuzumab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2, Neratini | 02/28 | 11/28 | | |
NCT06404775: External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women With Severe Mastalgia |
|
|
| Not yet recruiting | 3 | 456 | RoW | mastalgia-oil, tamoxifen placebo, mastalgia-oil placebo, tamoxifen | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Mastalgia | 05/28 | 05/29 | | |
NCT05165069: The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome |
|
|
| Recruiting | 3 | 234 | RoW | Mecobalamin 5 MG Disintegrating Oral Tablet, placebo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hand-foot Syndrome | 12/25 | 12/30 | | |
NCT05801705: Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study |
|
|
| Not yet recruiting | N/A | 700 | RoW | Aromatase inhibitor, ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist), Tamoxifen, toremifene | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk, Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen | 06/23 | 12/23 | | |
NCT05838001: Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy |
|
|
| Recruiting | N/A | 110 | RoW | Wire-guided localization and marker clip localization, marker clip localization | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer, Breast-conserving Surgery | 12/25 | 12/25 | | |
NCT04535466: Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics |
|
|
| Recruiting | N/A | 1000 | RoW | | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Diseases, Artificial Intelligence, Dense Breast Density, Predictive Cancer Model | 09/20 | 09/20 | | |
